NeuroSense Therapeutics Sets Annual Shareholder Meeting Date
Ticker: NRSNW · Form: 6-K · Filed: May 23, 2024 · CIK: 1875091
| Field | Detail |
|---|---|
| Company | Neurosense Therapeutics LTD. (NRSNW) |
| Form Type | 6-K |
| Filed Date | May 23, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, corporate-event, 6-K
TL;DR
NeuroSense sets AGM for June 27th, shareholders vote on company biz.
AI Summary
NeuroSense Therapeutics Ltd. announced on May 23, 2024, that it will hold its Annual General Meeting of Shareholders on June 27, 2024, at 11:00 a.m. Israel time. The meeting will take place at the company's offices located at 11 Hamenofim St., Building B, Herzliya, Israel. This announcement is made via a Form 6-K filing.
Why It Matters
The scheduling of the Annual General Meeting is a routine corporate event that allows shareholders to vote on important company matters and elect directors.
Risk Assessment
Risk Level: low — This filing is a routine corporate announcement regarding a shareholder meeting and does not contain new financial or operational information that would typically increase risk.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Registrant
- June 27, 2024 (date) — Annual General Meeting date
- 11:00 a.m. Israel time (time) — Annual General Meeting time
- 11 Hamenofim St., Building B, Herzliya 4672562, Israel (location) — Company's principal executive offices and meeting location
FAQ
When is NeuroSense Therapeutics Ltd.'s Annual General Meeting of Shareholders scheduled?
The Annual General Meeting of Shareholders is scheduled for June 27, 2024.
What time will the Annual General Meeting of Shareholders take place?
The meeting will take place at 11:00 a.m. Israel time.
Where will the Annual General Meeting of Shareholders be held?
The meeting will be held at the company's offices at 11 Hamenofim St., Building B, Herzliya 4672562, Israel.
What type of filing is this report?
This report is a Form 6-K, which is a Report of Foreign Private Issuer.
Does NeuroSense Therapeutics Ltd. file annual reports under Form 20-F or 40-F?
NeuroSense Therapeutics Ltd. files annual reports under Form 20-F.
Filing Stats: 280 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2024-05-23 16:00:25
Filing Documents
- ea0206776-6k_neurosense.htm (6-K) — 10KB
- ea020677601ex99-1_neurosense.htm (EX-99.1) — 11KB
- ex99-1_001.jpg (GRAPHIC) — 29KB
- 0001213900-24-046254.txt ( ) — 63KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: May 23, 2024 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 2